Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a clinicogenetic risk model risk model called m7-FLIPI for the identification of patients with early disease progression of follicular lymphoma after first-line immunotherapy. The m7-FLIPI identifies a series of genes associated with improved/reduced prognosis, information that can be added to the standard FLIPI model that identifies a group of high-risk follicular lymphoma patients. The results of a study to investigate the predictive utility of m7-FLIPI was presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.